• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因检测如何进行临床应用评估?英国基因检测网络的经验。

How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network.

作者信息

Kroese Mark, Zimmern Ron L, Farndon Peter, Stewart Fiona, Whittaker Joanne

机构信息

Public Health Genetics Unit, Cambridge, UK.

出版信息

Eur J Hum Genet. 2007 Sep;15(9):917-21. doi: 10.1038/sj.ejhg.5201867. Epub 2007 May 30.

DOI:10.1038/sj.ejhg.5201867
PMID:17534375
Abstract

The UK Department of Health supported the establishment of the UK Genetic Testing Network (UKGTN) in 2002. The UKGTN is a collaborative network of NHS molecular genetic laboratories that offer tests for human single gene germ-line disorders. Its objective is to provide high quality and equitable services for patients and their families who require genetic advice, diagnosis and management. The UKGTN has developed a 'Gene Dossier' process to evaluate genetic tests and recommend which tests will be provided by the National Health Service. This paper describes the UKGTN organisation and the 'Gene Dossier' process. A brief review of the UKGTN genetic test evaluation experience is presented.

摘要

英国卫生部于2002年支持建立了英国基因检测网络(UKGTN)。UKGTN是一个由国民保健制度(NHS)分子遗传学实验室组成的协作网络,这些实验室提供针对人类单基因种系疾病的检测。其目标是为需要基因咨询、诊断和管理的患者及其家庭提供高质量且公平的服务。UKGTN开发了一种“基因档案”流程,用于评估基因检测,并推荐哪些检测将由国家医疗服务体系提供。本文描述了UKGTN的组织架构和“基因档案”流程。还简要回顾了UKGTN基因检测评估经验。

相似文献

1
How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network.基因检测如何进行临床应用评估?英国基因检测网络的经验。
Eur J Hum Genet. 2007 Sep;15(9):917-21. doi: 10.1038/sj.ejhg.5201867. Epub 2007 May 30.
2
A framework for the prioritization of investment in the provision of genetic tests.提供基因检测的投资优先级框架。
Public Health Genomics. 2010;13(7-8):538-43. doi: 10.1159/000294278. Epub 2010 Mar 15.
3
Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders.遗传代谢病生化遗传检测和新生儿筛查的良好实验室规范。
MMWR Recomm Rep. 2012 Apr 6;61(RR-2):1-44.
4
Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.更新:英国遗传学服务机构对2018年英国癌症基因组学联盟/英国遗传检测网络乳腺癌基因检测面板指南的不同实施情况。
J Med Genet. 2021 Aug;58(8):579-580. doi: 10.1136/jmedgenet-2020-107529. Epub 2021 Feb 10.
5
Delivery of genetic screening services.基因筛查服务的提供
Birth Defects Orig Artic Ser. 1992;28(3):60-7.
6
The Scottish molecular genetics consortium--15 years on.苏格兰分子遗传学联盟——十五年回顾
Health Bull (Edinb). 2002 Jan;60(1):83-90.
7
A UK National External Quality Assessment scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia.
Thromb Haemost. 1999 Nov;82(5):1556-7.
8
Twenty-first-century medical microbiology services in the UK.英国21世纪的医学微生物学服务。
Nat Rev Microbiol. 2005 Dec;3(12):979-83. doi: 10.1038/nrmicro1291.
9
A collaborative approach to enabling stratified cancer medicine in the UK.在英国实现分层癌症医学的协作方法。
Drug Discov Today. 2015 Dec;20(12):1414-8. doi: 10.1016/j.drudis.2015.07.001. Epub 2015 Jul 29.
10
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.美国临床肿瘤学会政策声明更新:癌症易感性基因检测
J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189. Epub 2003 Apr 11.

引用本文的文献

1
Navigating Genetic Testing in Nephrology: Options and Decision-Making Strategies.肾内科中的基因检测导航:选择与决策策略
Kidney Int Rep. 2024 Dec 27;10(3):673-695. doi: 10.1016/j.ekir.2024.12.020. eCollection 2025 Mar.
2
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder.用于治疗重度抑郁症的药物遗传学临床决策支持系统的荟萃分析。
Pharmacogenomics J. 2023 May;23(2-3):45-49. doi: 10.1038/s41397-022-00295-3. Epub 2022 Oct 22.
3
A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies.
系统评价在组学技术卫生技术评估中使用的价值评估框架及其在 HTA 机构中的实际应用。
Int J Environ Res Public Health. 2020 Oct 30;17(21):8001. doi: 10.3390/ijerph17218001.
4
Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities.评估基因组学融入癌症筛查项目:挑战与机遇
Curr Genet Med Rep. 2019;7(2):63-74. doi: 10.1007/s40142-019-00162-x. Epub 2019 May 18.
5
A proposal of a new evaluation framework towards implementation of genetic tests.一种新的遗传检测实施评估框架的建议
PLoS One. 2019 Aug 5;14(8):e0219755. doi: 10.1371/journal.pone.0219755. eCollection 2019.
6
Healthcare System Priorities for Successful Integration of Genomics: An Australian Focus.基因组学成功整合的医疗保健系统优先事项:以澳大利亚为重点
Front Public Health. 2019 Mar 11;7:41. doi: 10.3389/fpubh.2019.00041. eCollection 2019.
7
How is genetic testing evaluated? A systematic review of the literature.遗传检测如何评估?文献系统评价。
Eur J Hum Genet. 2018 May;26(5):605-615. doi: 10.1038/s41431-018-0095-5. Epub 2018 Feb 8.
8
Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis.用于自身炎症和血管炎的靶向新一代测序基因检测板的临床影响
PLoS One. 2017 Jul 27;12(7):e0181874. doi: 10.1371/journal.pone.0181874. eCollection 2017.
9
Application of personalized medicine to chronic disease: a feasibility assessment.个性化医学在慢性病中的应用:可行性评估。
Clin Transl Med. 2013 Dec 18;2(1):16. doi: 10.1186/2001-1326-2-16.
10
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders.公共卫生框架下的基因检测与常见疾病:如何评估相关性及可能性。欧洲人类遗传学学会关于基因检测与常见疾病建议的背景文件
Eur J Hum Genet. 2011 Apr;19 Suppl 1(Suppl 1):S6-44. doi: 10.1038/ejhg.2010.249.